Acute megakaryoblastic leukemia laboratory findings

Jump to navigation Jump to search

Acute megakaryoblastic leukemia Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute megakaryoblastic leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute megakaryoblastic leukemia laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute megakaryoblastic leukemia laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute megakaryoblastic leukemia laboratory findings

CDC on Acute megakaryoblastic leukemia laboratory findings

Acute megakaryoblastic leukemia laboratory findings in the news

Blogs on Acute megakaryoblastic leukemia laboratory findings

Directions to Hospitals Treating Acute megakaryoblastic leukemia

Risk calculators and risk factors for Acute megakaryoblastic leukemia laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Laboratory Findings

The diagnosis of AMKL (M7) is based on the following:

  1. Bone marrow biopsy demonstrating 30% or more leukemic cells of megakaryocytic lineage
  2. Conducting tests that detect platelet-specific antibodies which could be monoclonal or polyclonal.
  3. Bone marrow biopsy is recommended in patients who developed myelofibrosis. Visualization of blasts and mature megakaryocytes on biopsy sections is diagnostic.

References

Template:WH Template:WS